In vitro activity of β-lactams in combination with avibactam against multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Achromobacter xylosoxidans isolates from patients with cystic fibrosis
The in vitro activity of anti-pseudomonal β-lactams in combination with avibactam was evaluated against 54 multidrug-resistant non-fermenting Gram-negative bacilli isolated from cystic fibrosis patients. Avibactam increased and/or restored the antibacterial activities of ceftazidime and aztreonam against Pseudomonas aeruginosa and Stenotrophomonas maltophilia, respectively. No β-lactam–avibactam combination was active against Achromobacter xylosoxidans.
CastellaniC, DuffAJA, BellSC, HeijermanHGM, MunckA et al. ECFS best practice guidelines: the 2018 revision. J Cyst Fibros2018; 17:153–178 [View Article][PubMed]
EdwardsBD, Greysson-WongJ, SomayajiR, WaddellB, WhelanFJ et al. Prevalence and outcomes of Achromobacter species infections in adults with cystic fibrosis: a North American cohort study. J Clin Microbiol2017; 55:2074–2085 [View Article][PubMed]
StefaniS, CampanaS, CarianiL, CarnovaleV, ColomboC et al. Relevance of multidrug-resistant Pseudomonas aeruginosa infections in cystic fibrosis. Int J Med Microbiol2017; 307:353–362 [View Article][PubMed]
SpenckerFB, StaberL, LietzT, SchilleR, RodloffAC. Development of resistance in Pseudomonas aeruginosa obtained from patients with cystic fibrosis at different times. Clin Microbiol Infect2003; 9:370–379 [View Article][PubMed]
LlanesC, PourcelC, RichardotC, PlésiatP, FichantG et al. Diversity of β-lactam resistance mechanisms in cystic fibrosis isolates of Pseudomonas aeruginosa: a French multicentre study. J Antimicrob Chemother2013; 68:1763–1771 [View Article][PubMed]
SantevecchiBA, SmithTT, MacVaneSH. Clinical experience with ceftazidime/avibactam for treatment of antibiotic-resistant organisms other than Klebsiella pneumoniae. Int J Antimicrob Agents2018; 51:629–635 [View Article][PubMed]
ChalhoubH, TunneyM, ElbornJS, VergisonA, DenisO et al. Avibactam confers susceptibility to a large proportion of ceftazidime-resistant Pseudomonas aeruginosa isolates recovered from cystic fibrosis patients. J Antimicrob Chemother2015; 70:1596–1598 [View Article][PubMed]
MushtaqS, WarnerM, LivermoreDM. In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters. J Antimicrob Chemother2010; 65:2376–2381 [View Article][PubMed]
European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Dieases (ESCMID) EUCAST definitive document E.DEF 3.1, June 2000: determination of minimum inhibitory concentrations (MICs) of antibacterial agents by agar dilution. Clin Microbiol Infect2000; 6:509–515[PubMed]
MojicaMF, Papp-WallaceKM, TaracilaMA, BarnesMD, RutterJD et al. Avibactam restores the susceptibility of clinical isolates of Stenotrophomonas maltophilia to aztreonam. Antimicrob Agents Chemother2017; 61:e00777-17 [View Article][PubMed]
BadorJ, AmoureuxL, DuezJM, DrabowiczA, SieborE et al. First description of an RND-type multidrug efflux pump in Achromobacter xylosoxidans, AxyABM. Antimicrob Agents Chemother2011; 55:4912–4914 [View Article][PubMed]
MojicaMF, OuelletteCP, LeberA, BecknellMB, ArduraMI et al. Successful treatment of bloodstream infection due to metallo-β-lactamase-producing Stenotrophomonas maltophilia in a renal transplant patient. Antimicrob Agents Chemother2016; 60:5130–5134 [View Article][PubMed]
In vitro activity of β-lactams in combination with avibactam against multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Achromobacter xylosoxidans isolates from patients with cystic fibrosis